Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy

Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor and potent inhibitor of PARP1, PARP2 and PARP3 enzymes. Phase II and III trials have documented that rucaparib has single-agent antitumor activity in patients with high-grade ovarian carcinoma, with both BRCA-mutated (germline and somatic)...

Descripción completa

Detalles Bibliográficos
Autores principales: Dal Molin, Graziela Z., Omatsu, Kohei, Sood, Anil K., Coleman, Robert L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024342/
https://www.ncbi.nlm.nih.gov/pubmed/29977351
http://dx.doi.org/10.1177/1758835918778483
_version_ 1783336042983587840
author Dal Molin, Graziela Z.
Omatsu, Kohei
Sood, Anil K.
Coleman, Robert L.
author_facet Dal Molin, Graziela Z.
Omatsu, Kohei
Sood, Anil K.
Coleman, Robert L.
author_sort Dal Molin, Graziela Z.
collection PubMed
description Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor and potent inhibitor of PARP1, PARP2 and PARP3 enzymes. Phase II and III trials have documented that rucaparib has single-agent antitumor activity in patients with high-grade ovarian carcinoma, with both BRCA-mutated (germline and somatic) and with homologous recombination deficiency (HRD). Rucaparib as a maintenance treatment showed increased progression-free survival in patients with ovarian carcinoma who achieved a response to platinum-based chemotherapy, with an acceptable safety profile. The approval of this drug, along with the companion diagnostic FoundationFocus CDxBRCA test represents an important new therapeutic option in the treatment of ovarian cancer. This article reviews the mechanisms of action, safety, pharmacokinetics and pharmacodynamics and indications for use of rucaparib as well as future trials.
format Online
Article
Text
id pubmed-6024342
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-60243422018-07-05 Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy Dal Molin, Graziela Z. Omatsu, Kohei Sood, Anil K. Coleman, Robert L. Ther Adv Med Oncol Review Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor and potent inhibitor of PARP1, PARP2 and PARP3 enzymes. Phase II and III trials have documented that rucaparib has single-agent antitumor activity in patients with high-grade ovarian carcinoma, with both BRCA-mutated (germline and somatic) and with homologous recombination deficiency (HRD). Rucaparib as a maintenance treatment showed increased progression-free survival in patients with ovarian carcinoma who achieved a response to platinum-based chemotherapy, with an acceptable safety profile. The approval of this drug, along with the companion diagnostic FoundationFocus CDxBRCA test represents an important new therapeutic option in the treatment of ovarian cancer. This article reviews the mechanisms of action, safety, pharmacokinetics and pharmacodynamics and indications for use of rucaparib as well as future trials. SAGE Publications 2018-06-22 /pmc/articles/PMC6024342/ /pubmed/29977351 http://dx.doi.org/10.1177/1758835918778483 Text en © The Author(s), 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Dal Molin, Graziela Z.
Omatsu, Kohei
Sood, Anil K.
Coleman, Robert L.
Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy
title Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy
title_full Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy
title_fullStr Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy
title_full_unstemmed Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy
title_short Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy
title_sort rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024342/
https://www.ncbi.nlm.nih.gov/pubmed/29977351
http://dx.doi.org/10.1177/1758835918778483
work_keys_str_mv AT dalmolingrazielaz rucaparibinovariancanceranupdateonsafetyefficacyandplaceintherapy
AT omatsukohei rucaparibinovariancanceranupdateonsafetyefficacyandplaceintherapy
AT soodanilk rucaparibinovariancanceranupdateonsafetyefficacyandplaceintherapy
AT colemanrobertl rucaparibinovariancanceranupdateonsafetyefficacyandplaceintherapy

Ejemplares similares